Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients
Ashleigh Porter(University of California, Los Angeles), Ezra E.W. Cohen(Moores Cancer Center), Gregory A. Daniels(University of California San Diego), Julie Bykowski(University of California, San Diego), Kimberly C. Banks(Guardant (United States)), Assuntina G. Sacco(University of California San Diego), Sandip Pravin Patel(University of California San Diego), Mandy Natsuhara(Moores Cancer Center)
Cited by 28
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k